Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 20/20 | 0.76 |
| ▸ | MMP13 | P45452 | 5/20 | 0.72 |
| ▸ | MMP2 | P08253 | 1/20 | 0.72 |
| ▸ | MMP3 | P08254 | 1/20 | 0.72 |
| ▸ | MMP7 | P09237 | 1/20 | 0.72 |
| ▸ | MMP9 | P14780 | 1/20 | 0.72 |
| ▸ | MMP8 | P22894 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13144496 | 0.96 | MMP12 (0.71) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3085336 | 0.96 | MMP12 (0.71) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL8092276 | 0.86 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3072228 | 0.86 | MMP12 (0.75) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3073064 | 0.86 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3065667 | 0.85 | MMP12 (0.81) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3065843 | 0.85 | MMP12 (0.74) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3079237 | 0.84 | MMP12 (0.82) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3081114 | 0.84 | MMP12 (1.00) | MMP12MMP13MMP2MMP3MMP7 | |
| SCHEMBL3085462 | 0.83 | MMP12 (0.81) | MMP12MMP13MMP2MMP3MMP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | claimed |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO KGAA (DE) | 2021-06-10 | — | — | US | disclosed |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2016-05-19 | — | — | US | disclosed |
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (GE) | 2014-12-18 | — | — | US | disclosed |
| EP-2260839-A2 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | Merz Pharma GmbH & Co. KGaA (DE) | 2010-12-15 | — | — | EP | disclosed |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-09-09 | — | — | US | disclosed |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | WYETH LLC | 2010-09-09 | — | — | US | disclosed |
| US-6828462-B2 | Amines such as 3,3,5,5-Tetramethyl-1-vinylcyclohexanamine hydrochloride, used as N-methyl-D-aspartate (NMDA), serotonin and nicotinic acetylcholine receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-12-07 | — | — | US | disclosed |
| EP-1442008-A1 | UNSATURATED 1-AMINO-ALKYLCYCLOHEXANE NMDA, 5HT3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS | Merz Pharma GmbH & Co. KGaA (DE) | 2004-08-04 | — | — | EP | disclosed |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20030166634-A1 | Unsaturated 1-Amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | MERZ PHARMA GMBH & CO. KGAA (DE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003040084-A1 | UNSATURATED 1-AMINO-ALKYLCYCLOHEXANE NMDA, 5HT3 AND NEURONAL NICOTINIC RECEPTOR ANTAGONISTS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371260-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, BACE1, CHRNE | MMP12 1040/4885MMP13 3394/4885MMP2 2161/4885 |
| US-20100227852-A1 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors | ACHE, BACE1, CHRNE | MMP12 1040/4885MMP13 3394/4885MMP2 2161/4885 |
| US-20160136144-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | MMP12 647/4885MMP13 3135/4885MMP2 1541/4885 |
| US-20210169864-A1 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | ACHE, PSEN1, BCHE | MMP12 647/4885MMP13 3135/4885MMP2 1541/4885 |
| US-20100227859-A1 | TRICYCLIC COMPOUNDS AS MATRIX METALLOPROTEINASE INHIBITORS | MMP13, MMP2, MMP12 | MMP12 3/4885MMP13 1/4885MMP2 2/4885 |
| US-20040087658-A1 | Synergistic mixture; Alzheimer's disease therapy | ACHE, BACE1, CHRNA5 | MMP12 1285/4885MMP13 3265/4885MMP2 2729/4885 |
| US-20030166634-A1 | Unsaturated 1-Amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists | GRIN3A, GRIN2A, GRIN1 | MMP12 4472/4885MMP13 3927/4885MMP2 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.